Bayer Sues J&J Over Prostate Cancer Drug Advertising Claims

Lawsuit alleges J&J falsely claimed Erleada had a 51% risk reduction compared to Bayer's Nubeqa drug.

Published on Feb. 23, 2026

Got story updates? Submit your updates here. ›

Bayer AG has filed a lawsuit against Johnson & Johnson (J&J) in Manhattan federal court, alleging that J&J made false advertising claims about the efficacy of its prostate cancer drug Erleada compared to Bayer's drug Nubeqa. Bayer claims J&J's comparison was based on flawed analysis and selection bias, and that the company misled patients and healthcare providers by invoking FDA authority to lend credibility to the scientifically flawed data.

Why it matters

The dispute highlights the intense competition in the multibillion-dollar prostate cancer treatment market, where market share is fiercely contested. A successful lawsuit could not only halt J&J's advertising campaign but also result in significant financial penalties, impacting the companies' financial performance and potentially leading to a reassessment of marketing strategies in the broader pharmaceutical industry.

The details

Bayer alleges that J&J falsely claimed patients treated with Erleada experienced a '51% reduction in risk of death' compared to those treated with Nubeqa. Bayer argues this claim is misleading because the comparison was based on a flawed analysis where the majority of Nubeqa patients were using the drug 'off-label,' creating a selection bias. Bayer also says J&J's study included five times more patients than the Nubeqa comparison group, further skewing the results. Bayer contends the FDA does not endorse the type of retrospective, real-world analysis J&J allegedly used instead of traditional clinical trials.

  • Bayer filed the lawsuit against J&J on February 23, 2026.

The players

Bayer AG

A multinational pharmaceutical and life sciences company that manufactures the prostate cancer drug Nubeqa.

Johnson & Johnson (J&J)

A multinational corporation that manufactures the prostate cancer drug Erleada.

Erleada

J&J's prostate cancer drug that is at the center of the advertising dispute.

Nubeqa

Bayer's prostate cancer drug that is being compared to Erleada in the lawsuit.

Got photos? Submit your photos here. ›

What’s next

The lawsuit is likely to be a lengthy and complex legal battle, with the outcome potentially setting a precedent for future disputes over drug marketing claims and influencing how companies present data to promote their products.

The takeaway

This case highlights the intense competition and marketing practices within the pharmaceutical industry, as well as the importance of transparent and accurate data presentation to maintain public trust. The outcome could have significant financial and regulatory implications for both Bayer and J&J, as well as the broader healthcare landscape.